Multi-epitope mRNA Vaccine for SARS-CoV-2 Variant Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against SARS-CoV-2 face challenges due to emerging viral variants, which can evade neutralizing antibodies, leading to reduced vaccine efficacy over time and increased transmissibility.
Innovation Solution
Development of mRNA multi-epitope vaccines that incorporate well-conserved T-cell epitopes, identified through structure-based network analysis, to induce strong CD8+ T-cell responses and potentially broaden immunity against various SARS-CoV-2 variants and other sarbecoviruses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current mRNA vaccines use spike protein to induce neutralizing antibodies, then initial vaccine efficacy is achieved, but efficacy declines rapidly over time due to viral variants evading antibody recognition
Solution Approach 1:
The vaccine design segments the immunogenic spike protein into multiple distinct epitope regions (S1, S2, RDB, TM) and combines them with conserved epitopes from other sarbecoviruses. This segmentation allows the vaccine to target multiple viral variants simultaneously, preventing the rapid efficacy decline caused by single-epitope viral escape mutations.
Solution Approach 2:
The multi-epitope vaccine construct is designed to provide universal protection against multiple SARS-CoV-2 variants and related sarbecoviruses. By incorporating conserved epitopes from SARS-CoV-1, SARS-CoV-2, and other betacoronaviruses, the vaccine achieves broad-spectrum immunity that maintains reliability across different viral strains and over extended time periods.
2Adaptability or versatility
If vaccines target only neutralizing antibodies against spike protein, then initial immune response is generated, but immunity fails against heavily mutated variants like Omicron
Solution Approach 1:
The vaccine merges multiple epitope sequences from different viral sources (SARS-CoV-1, SARS-CoV-2, and other betacoronaviruses) into a single immunogenic construct. This combination includes conserved T-cell epitopes and B-cell epitopes that are recognized across variants, thereby expanding adaptability while maintaining reliability against heavily mutated strains.
Solution Approach 2:
The immunogenic spike protein is designed as a composite structure containing epitopes from multiple viral origins. This composite approach integrates conserved regions that are less prone to mutation with variant-specific neutralizing epitopes, creating a multi-layered immune response that adapts to viral diversity while maintaining protective reliability.
3Measurement precision
If vaccine design focuses on single epitope recognition, then specific immune response is induced, but immune escape through mutation of that epitope occurs
Solution Approach 1:
The vaccine segments the immunogenic protein into multiple epitope modules, each targeting different viral regions. This segmentation ensures that if one epitope undergoes mutation and escapes recognition, other epitopes remain intact and continue to elicit protective immune responses, thereby maintaining adaptability while preserving measurement precision of immune recognition.
Data Source
AI summary
In various embodiments immunogenic nanoparticles are provided that are capable of raising an immune response directed against SARS-CoV-2. In certain embodiments the immunogenic nanoparticles comprise mRNA multi-epitope vaccines that can be used in combination with or independent of other covid-19 vaccines (e.g., the spike protein mRNA vaccine(s)) to invoke a strong CD8+ or CD4+ T-cell as well as neutralizing antibody producing B-cell responses. In certain embodiments this vaccine is based on the rational combination of well-conserved T- and B-cell epitopes identified COVID-19 and viral variants.